company background image
0QYQ

Gilead Sciences LSE:0QYQ Stock Report

Last Price

US$84.18

Market Cap

US$105.4b

7D

0.6%

1Y

31.1%

Updated

05 Feb, 2023

Data

Company Financials +

0QYQ Stock Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

0QYQ fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance2/6
Financial Health5/6
Dividends3/6

My Notes

New

Notes are coming soon

Gilead Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share PriceUS$84.18
52 Week HighUS$89.58
52 Week LowUS$57.20
Beta0.43
1 Month Change-4.52%
3 Month Change3.54%
1 Year Change31.12%
3 Year Change22.05%
5 Year Change7.62%
Change since IPO-1.50%

Recent News & Updates

Recent updates

Shareholder Returns

0QYQGB BiotechsGB Market
7D0.6%-0.05%1.8%
1Y31.1%-24.7%-3.7%

Return vs Industry: 0QYQ exceeded the UK Biotechs industry which returned -24.7% over the past year.

Return vs Market: 0QYQ exceeded the UK Market which returned -3.7% over the past year.

Price Volatility

Is 0QYQ's price volatile compared to industry and market?
0QYQ volatility
0QYQ Average Weekly Movement2.8%
Biotechs Industry Average Movement8.4%
Market Average Movement5.1%
10% most volatile stocks in GB Market11.0%
10% least volatile stocks in GB Market2.7%

Stable Share Price: 0QYQ is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 0QYQ's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198714,400Dan O'Dayhttps://www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
0QYQ fundamental statistics
Market CapUS$105.37b
Earnings (TTM)US$4.59b
Revenue (TTM)US$27.28b

22.9x

P/E Ratio

3.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
0QYQ income statement (TTM)
RevenueUS$27.28b
Cost of RevenueUS$5.66b
Gross ProfitUS$21.62b
Other ExpensesUS$17.03b
EarningsUS$4.59b

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)3.68
Gross Margin79.26%
Net Profit Margin16.83%
Debt/Equity Ratio0%

How did 0QYQ perform over the long term?

See historical performance and comparison

Dividends

3.5%

Current Dividend Yield

80%

Payout Ratio